NCT00705653 - Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Cancer

Interventions

DRUG

PG-11047

PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).

Trial Locations (1)

60637

University of Chicago, Cancer Research Centre, Chicago